

October 4, 2010

Mitsubishi Tanabe Pharma Corporation

**Revision to First Half and Full Year Consolidated Financial Forecasts
for Fiscal Year Ending March 31, 2011**

Osaka, Japan, October 04, 2010--Mitsubishi Tanabe Pharma Corporation announced today the revision to first half and full year consolidated financial forecasts for fiscal year ending March 31, 2011, which was announced on July 29 and May 12, 2010, respectively.

1. Revised first half year consolidated financial forecasts for the fiscal year ending March 31, 2011 (April 1, 2010 to September 30, 2010)

	Sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A)	Millions of yen 198,000	Millions of yen 31,000	Millions of yen 31,000	Millions of yen 16,000	Yen 28.51
Revised forecast (B)	204,000	39,000	39,000	22,000	39.20
Difference (B-A)	6,000	8,000	8,000	6,000	-
Percentage of change %	3.0	25.8	25.8	37.5	-
(Reference) Results in the same period of the previous fiscal year	198,239	27,456	27,910	13,552	24.15

2. Revised full year consolidated financial forecasts for the fiscal year ending March 31, 2011 (April 1, 2010 to March 31, 2011)

	Sales	Operating income	Ordinary income	Net income	Net income per share
Previous forecast (A)	Millions of yen 380,000	Millions of yen 55,000	Millions of yen 55,000	Millions of yen 27,000	Yen 48.11
Revised forecast (B)	401,000	67,000	67,000	35,500	63.26
Difference (B-A)	21,000	12,000	12,000	8,500	-
Percentage of change %	5.5	21.8	21.8	31.5	-
(Reference) Results in the same period of the previous fiscal year	404,747	61,475	61,649	30,253	53.91

3. Reason for revision

For the first six months of the fiscal year ended March 31, 2011 (April 1, 2010 to September 30, 2010), the Company's current results forecasts exceed the previously announced results forecasts. The reasons for this revision include favorable sales of core products in the domestic market for ethical drugs, such as Remicade and Radicut, and the fact that the influence of the administrative action regarding Medway Injection remains insignificant at this point.

In addition to an increase in sales, expenses decrease mainly because the generation of SG&A expenses is expected to be recorded in the third quarterly period and subsequent periods. In profits, operating income, ordinary income, and net income for the first six months of the fiscal year are now expected to exceed the previous forecasts.

Moreover, in consideration of the current results forecast for the first six months of the fiscal year, the Company will also revise the previous results forecasts for the full year.

Note: The above results forecasts reflect judgments and assumptions that are based on information available at the present point in time. For any of a number of reasons, actual results might differ materially from these forecasts.